Morning Overview on MSN
The FDA approved a lower-dose contrast agent to cut patients’ exposure during MRI scans
Patients who need repeated MRI scans with contrast dye could soon receive a fraction of the gadolinium they currently get. The FDA approved gadoquatrane, a new gadolinium-based contrast agent designed ...
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
The rate of hypersensitivity reactions (HSRs) to gadolinium-based contrast agents (GBCAs) is 0.4 percent, and premedication can reduce the risk for HSRs in patients with a history of acute or delayed ...
A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...
Skoltech researchers and their colleagues have synthesized and tested protein-polymer microbubbles for use in medical ultrasound imaging of internal organs. Administered intravenously, the ...
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...
The FDA has approved Ambelvist, a macrocyclic gadolinium-based option for contrast-enhanced MRI, now the lowest ...
The FDA has approved Bayer’s Ambelvist (gadoquatrane), the lowest-dose macrocyclic GBCA for adult and pediatric contrast-enhanced CNS and body MRI exams.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results